Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms

Pharmiweb.com RSS Feed Pharmiweb.com RSS Feeds

Advertising

Press Release

Global Drug Analysis: TetraVax-DV - A Potential Best-in-Class Live-Attenuated Vaccine - ResearchAndMarkets.com

Research and Markets
Posted on: 15 Feb 18

The "Drug Analysis: TetraVax-DV" drug pipelines has been added to ResearchAndMarkets.com's offering.

TetraVax-DV is a lyophilized, tetravalent, live-attenuated chimeric vaccine currently in Phase II/III development. The viral strains were formulated by the US National Institutes of Health (NIH) and have been licensed by vaccine producers in India (Biological E/Panacea Biotec), Brazil (Butantan Institute), and Vietnam (Vabiotech). Merck & Co has also in-licensed the vaccine from the NIH in order to investigate the potential of a heterologous prime-boost strategy with its own in-house vaccine, V180 (adjuvanted, tetravalent DEN-80E subunit vaccine).

TetraVax-DV has emerged as a potential best-in-class live-attenuated vaccine based on Phase I studies, which showed impressive rates of tetravalent seroconversion after a single dose of the TV-003 and TV-005 formulations. It is expected that the vaccine's low production costs and anticipated lower price compared to the other tetravalent live-attenuated chimeric vaccines, Dengvaxia (Sanofi Pasteur) and TAK-003 (Takeda), will allow local manufacturers to dominate their respective domestic markets. In addition, the Butantan Institute is expected to export TetraVax-DV to other endemic Latin American markets from Q2 2019, greatly reducing the commercial attractiveness of this region for other vaccines companies. Aside from dengue-endemic markets, TetraVax-DV's impressive immunogenicity in flavivirus-nave recipients and its attractive dosing schedule also position it as a strong candidate for travelers and/or the military.

Key Topics Covered:

Product Profiles

TetraVax-DV: Dengue vaccines

List of Figures

Figure 1: Design of the TetraVax-DV vaccine

Figure 2: TetraVax-DV for dengue fever - SWOT analysis

List of Tables

Table 1: TetraVax-DV drug profile

Table 2: TetraVax-DV completed studies in dengue fever

Table 3: TetraVax-DV ongoing studies in dengue fever

For more information about this drug pipelines report visit https://www.researchandmarkets.com/research/jgwzs3/global_drug?w=4

View source version on businesswire.com: http://www.businesswire.com/news/home/20180215005659/en/

Business Wire
www.businesswire.com

Last updated on: 15/02/2018

Advertising
Site Map | Privacy & Security | Cookies | Terms and Conditions

PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.